Merck & Co., Inc.
Drugmaker with rare disease work · based in Rahway, United States · founded 1891 · ticker MRK · merck.com
Merck & Co., Inc. works on 23 rare diseases we track, including Acute Myeloid Leukemia, Adrenocortical Carcinoma and 21 more. It has 30 active clinical trials, and 13 are looking for volunteers now. It also has 5 FDA-approved rare disease drugs.
Merck is a global pharmaceutical company with a substantial rare disease presence through oncology and cardiovascular programs. The company's Keytruda franchise covers rare cancers including Merkel cell carcinoma and mesothelioma, while Winrevair (sotatercept) became the first activin signaling inhibitor approved for pulmonary arterial hypertension in 2024.
Merck & Co., Inc. pipeline
Each row lists the diseases Merck & Co., Inc. is studying at that stage, from the ones closest to approval down to the earliest work.
Keytruda (pembrolizumab) · Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) · Welireg (belzutifan) · Winrevair (sotatercept-csrk) · Isentress (raltegravir)
Myasthenia Gravis recruiting · Essential Thrombocythemia recruiting · Pulmonary Arterial Hypertension · Myelodysplastic Syndromes
Merkel Cell Carcinoma 2 trials recruiting · Pheochromocytoma recruiting · Non-cystic Fibrosis Bronchiectasis recruiting · Primary Central Nervous System Lymphoma recruiting · Multiple Myeloma recruiting · Desmoid Tumors recruiting · Beta-Thalassemia recruiting · Essential Thrombocythemia 2 trials · Niemann-Pick Disease Type C · Hodgkin Lymphoma · and 6 more
Healthy Participants recruiting · Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma recruiting · Acute Myeloid Leukemia recruiting · Neurofibromatosis Type 1 · Multiple Myeloma
Leukodystrophy recruiting · Multiple Sclerosis · Spinal Muscular Atrophy
Merck & Co., Inc. clinical trials
These are Merck & Co., Inc. trials for the rare diseases we track, from ClinicalTrials.gov. Statuses there can lag behind company news, so confirm with the study team before you plan around one.
13 trials looking for volunteers now
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
Tests Placebo, Cladribine Low Dose, Cladribine High Dose
For Generalized Myasthenia Gravis
A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007)
Tests Fluzone® High-Dose (HD) influenza vaccine, MK-1406 Injection, Placebo
For Healthy Participants
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Tests Belzutifan
For Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor and HIF-2α Mutated Cancers
The Myelin Disorders Biorepository Project
For Leukodystrophy, White Matter Disease, Leukoencephalopathies, 4H Syndrome and Adrenoleukodystrophy
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
Tests Bomedemstat
For Thrombocythemia, Essential, Primary Myelofibrosis, Myelofibrosis, Post-polycythemia Vera Myelofibrosis and Post-essential Thrombocythemia Myelofibrosis
A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)
Tests MK-1045
For Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis
Tests Nebulized Ensifentrine Suspension; 3 mg, Nebulized Placebo Solution
For Non-cystic Fibrosis Bronchiectasis
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
Tests Ibrutinib, Pembrolizumab, Rituximab
For Primary Central Nervous System Lymphoma, Recurrent Cancer, Refractory Cancer and Relapsed Cancer
Pick a condition. One email when a new trial opens, a trial changes or the FDA decides, from any company, not only Merck & Co., Inc.. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
FDA-approved drugs from Merck & Co., Inc.
From the openFDA database. Tap a drug for side effects, dosing and help paying.
Keytruda pembrolizumab
For Mesothelioma, Merkel Cell Carcinoma and Hodgkin Lymphoma. Approved Sep 4, 2014. Taken by intravenous route.
Keytruda Qlex pembrolizumab and berahyaluronidase alfa-pmph
For Mesothelioma and Merkel Cell Carcinoma. Approved Sep 19, 2025. Taken by subcutaneous route.
Welireg belzutifan
For Paraganglioma and Pheochromocytoma. Approved Aug 13, 2021.
Winrevair sotatercept-csrk
For Pulmonary Arterial Hypertension. Approved Mar 26, 2024.
Isentress raltegravir
For Huntington Disease. Taken by mouth.
More about Merck & Co., Inc.
Within its broader pharmaceutical portfolio, Merck & Co., Inc. has active clinical trial programs and drug development efforts across 23 rare diseases, including Acute Myeloid Leukemia, Adrenocortical Carcinoma, Cholangiocarcinoma, Essential Thrombocythemia, Gastrointestinal Stromal Tumor, and 18 additional rare conditions. These programs may span orphan drug designation, novel therapeutic mechanisms, and precision medicine approaches targeting the underlying causes of each disease.
The clinical trials section below shows active and recruiting rare disease studies sponsored by Merck & Co., Inc., sourced live from ClinicalTrials.gov. Each trial includes its current recruitment status, study phase (Phase 1 through Phase 4), conditions under investigation, and the number of active trial sites.
The FDA-approved drugs section lists treatments that have received U.S. Food and Drug Administration approval, with brand names, generic names, approval dates, and matched rare disease indications from the openFDA database.
Merck & Co., Inc. is headquartered in Rahway, United States, founded in 1891, publicly traded under the ticker symbol MRK. The company maintains a dedicated rare disease division alongside its broader therapeutic portfolio, working to bring innovative treatments to patients with conditions that have historically had limited or no treatment options.
Where Merck & Co., Inc. trials take place
The trials above run at 1,192 study sites in 48 countries. Tap a country to see its states, cities and hospitals.
Rare diseases Merck & Co., Inc. works on
Each disease page lists every open trial, not only Merck & Co., Inc.'s, plus approved treatments.
Acute myeloid leukemia (AML) is a fast-growing cancer of the bone marrow in which immature white blood cells called blasts crowd out normal blood cells, causing fatigue, infections and bleeding...
How common: The National Cancer Institute's SEER program estimates 22,720 new US cases and 11,500 deaths in 2026, about 1.1% of new cancers, and 83,311 people were living with AML in 2023
Adrenocortical carcinoma is a rare, aggressive cancer of the adrenal cortex, the outer layer of the adrenal glands that sit on top of each kidney.
How common: About 1-2 per million people per year; approximately 600 new cases per year in the U.S
Cholangiocarcinoma is a rare and aggressive cancer that forms in the bile ducts, the thin tubes that carry digestive fluid (bile) from the liver to the small intestine.
How common: About 8,000 new cases per year in the U.S.; rising incidence worldwide
Essential Thrombocythemia is a myeloproliferative neoplasm characterized by overproduction of platelets by bone marrow, resulting in very high platelet counts.
How common: About 1 new case per 100,000 people each year, with an estimated 30 to 60 per 100,000 living with it (NORD); average age at diagnosis is in the mid-fifties
Gastrointestinal Stromal Tumor
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract, arising from the interstitial cells of Cajal or their precursors.
How common: About 6,000 new cases per year in the U.S. (American Cancer Society); true incidence may be higher as small GISTs are often incidentally discovered
Hodgkin lymphoma is a cancer of the lymphatic system characterized by the presence of abnormal Reed-Sternberg cells.
How common: About 8,920 new cases expected in the U.S. in 2026 (American Cancer Society); approximately 2.6 per 100,000 people
Mantle cell lymphoma is a rare type of non-Hodgkin lymphoma that starts in B cells, a kind of white blood cell.
How common: About 1 in 200,000 people (Cleveland Clinic)
Merkel cell carcinoma is a rare, aggressive skin cancer that arises from Merkel cells, specialized touch receptors in the skin.
How common: About 2,500 new U.S. cases in 2013, projected to pass 3,000 a year by 2025; reported cases nearly doubled from 2000 to 2013 (Paulson, 2018)
Where to get support
Patient groups can explain a diagnosis, point you to specialists and tell you about trials before they open. Merck & Co., Inc.'s own site is merck.com, and our help paying for treatment page lists drugmaker programs and charity funds.
- National Cancer Institute - Adrenocortical CarcinomaAdrenocortical Carcinoma and Cholangiocarcinoma and 2 more
- NIH GARD - Neurofibromatosis Type 1Neurofibromatosis Type 1 and Paraganglioma and 2 more
- NCI SEER Cancer Stat Facts: Acute Myeloid LeukemiaAcute Myeloid Leukemia
- NCI PDQ: Acute Myeloid Leukemia Treatment, patient versionAcute Myeloid Leukemia
- ENSAT - European Network for Adrenal TumorsAdrenocortical Carcinoma
- Cholangiocarcinoma FoundationCholangiocarcinoma
- National Organization for Rare Disorders (NORD)Essential Thrombocythemia
- Leukemia & Lymphoma SocietyEssential Thrombocythemia